Enanta Initiates Phase 1 Study On EDP-322, An Oral Antibiotic With Activity Against Hospital- And Community-Acquired MRSA Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective
drugs, announced today the initiation of a Phase 1 study on investigational oral antibiotic EDP-322, a first-in-class MRSA-active Bicyclolide, a novel macrolide-related drug class with a distinct resistance profile.
Source: www.medicalnewstoday.com
# posted by Network @ 6:00 AM
